Asian stocks were set to hold tight ranges on Friday after a mixed Wall Street session and as investors awaited key U.S. jobs data while sustained hopes about a global economic recovery kept pressure on the safe-haven dollar.
There’s no doubt about it, Moderna’s (MRNA) profile has increased dramatically since the pandemic’s onset.The biotech name has climbed 206% higher this year, as investors have piled in with the hope that its COVID-19 vaccine candidate, mRNA-1273, might be the one to solve the coronavirus conundrum. Yet, it hasn’t all been positive news. Recently, questions have surfaced concerning the company’s sale of shares following the stock’s latest surge.Blocking out all of the noise, Oppenheimer analyst Hartag Singh recently attended Moderna’s virtual Science Day to get some visibility on the work going on behind the scenes. The 5-star analyst liked what …read more […]
Airlines from America to Australia are ramping up flights in June and July, boosting hopes for a pickup in tourist traffic even as bigger-spending business and global travel remains sluggish during the ongoing pandemic.
Rewind to the end of 2019, and in the dead of winter, the sun appeared to be shining on biotech Amarin (AMRN). Vascepa, the company’s high triglycerides treatment and only product, had just received label expansion approval from the FDA, and a large commercial opportunity beckoned.But the rug was pulled out from underneath Amarin’s feet in one swift move. In March, the company lost a patent trial against two generic drug makers, Dr. Reddy’s and Hikma Pharmaceuticals, seeking to sell their own versions of Vascepa. Accordingly, a massive sell off ensued. Amarin has since filed its appeal, and the generic …read more […]
Editor’s Note: Today, Contributing Analyst Jody Chudley shares some of the simplest investing advice he’s ever received, but corporate America has still failed to take it to heart.
The truth is, many of the market’s top executives get distracted chasing the wrong metrics for success.
That’s why Chief Income Strategist Marc Lichtenfeld wants investors to avoid making the same mistake.
Instead of following the faulty metric Jody describes below, take a look at Marc’s March interview in U.S. News & World Report to discover which signals will best guide your portfolio.
>Click here to read the full interview. …read more […]
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of March 31st, 2020. […] …read more […]
You could have made 50% in one day with Party City (NYSE: PRTY) shares a week ago. It was a trend reversal following a massive downturn for the stock.
This obvious pariah of social distancing has seen its shares tank from $8 to $0.26 over the past year.
After all, who’s going to be throwing parties when the end result is possible death from the coronavirus?
Well, conventional wisdom is often wrong…
Just look at the move in casino stocks, airline stocks, hotel stocks and even theme park stocks since the lows in March. Some have doubled and even tripled.
Casinos reopened with bigger-than-expected crowds. …read more […]
Gap Inc on Thursday reported a quarterly loss of nearly $1 billion as the apparel retailer was forced to close its stores due to the coronavirus outbreak, sending its shares down about 8% after market hours.
Slack Technologies Inc on Thursday posted slowing quarterly sales growth, disappointing investors who had expected a surge in demand for its workplace messaging app as companies rapidly adopt remote working tools and technology.
Uber Technologies Inc on Thursday launched a feature on its food delivery app Uber Eats that allows customers in the United States and Canada to order from restaurants owned by black people.
A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc , a medical diagnostics company that develops tests to identify tuberculosis, with a $400 million acquisition offer, people familiar with the matter said on Thursday.
Slack Technologies Inc on Thursday withdrew its 2021 billing outlook and reported a 50% jump in quarterly sales that failed to surpass lofty investor expectations driven by a surge in demand for workplace messaging platforms as more companies shift to remote work.
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
